Zhejiang Hisun Pharmaceutical Co.Ltd(600267) announcement: on May 19, 2022, the company and Shanghai Wangshi Biomedical Technology Co., Ltd. (hereinafter referred to as “Wangshi biology”) signed the strategic cooperation agreement and the entrusted production framework agreement. The two sides intend to establish strategic cooperation relations in the fields of product processing, production, international registration and market development of small molecule innovative drug vv116, so as to realize the strategic objectives of complementary advantages, mutual benefit and win-win and common development. The listing license holder of vv116 products involved in the entrusted processing framework agreement is Wangshi biology. The company is only the entrusted manufacturer of the products and does not enjoy its ownership. The agreement only reached a framework agreement on the cooperation principle of entrusted production of vv116 products. The specific quantity, price and special requirements will be separately signed based on the entrusted production framework agreement. The main shareholders of Wangshi biology are Shanghai juntuo and others. Shanghai juntuo combines Wangshi biology and Shanghai juntuo is a Shanghai Junshi Biosciences Co.Ltd(688180) holding subsidiary.
© China Stock Market News